EMERGENT BIOSOLUTIONS INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $75.77 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-04
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $75.77M, a 7.56% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $161.64M, a 84.75% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $114.30M, a 18.20% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $63.61M, a 31.61% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $421.52M, a 42.27% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $296.28M, a 9.94% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $328.97M, a 16.72% increase from fiscal 2014.
- EMERGENT BIOSOLUTIONS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $281.85M, a 9.28% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $75.77M 10-Q · filed 2018-05-04 | $237.41M derived: sum of 2 quarters · filed 2018-05-04 | $351.71M derived: sum of 3 quarters · filed 2018-05-04 | $415.32M derived: sum of 4 quarters · filed 2018-05-04 | ||||
| 2017-12-31 | $161.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $275.94M derived: sum of 2 quarters · filed 2018-02-23 | $339.55M derived: sum of 3 quarters · filed 2018-02-23 | $421.52M 10-K · filed 2018-02-23 | ||||
| 2017-09-30 | $114.30M 10-Q · filed 2017-11-03 | $177.91M derived: sum of 2 quarters · filed 2017-11-03 | $259.88M 10-Q · filed 2017-11-03 | $347.37M derived: sum of 4 quarters · filed 2018-05-04 | ||||
| 2017-06-30 | $63.61M 10-Q · filed 2017-08-04 | $145.58M 10-Q · filed 2017-08-04 | $233.07M derived: sum of 3 quarters · filed 2018-05-04 | $329.77M derived: sum of 4 quarters · filed 2018-05-04 | ||||
| 2017-03-31 | $81.97M 10-Q · filed 2018-05-04 | $169.46M derived: sum of 2 quarters · filed 2018-05-04 | $266.16M derived: sum of 3 quarters · filed 2018-05-04 | $314.49M derived: sum of 4 quarters · filed 2018-05-04 | ||||
| 2016-12-31 | $87.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $184.19M derived: sum of 2 quarters · filed 2018-02-23 | $232.52M derived: sum of 3 quarters · filed 2018-02-23 | $296.28M 10-K · filed 2018-02-23 | ||||
| 2016-09-30 | $96.70M 10-Q · filed 2017-11-03 | $145.03M derived: sum of 2 quarters · filed 2017-11-03 | $208.78M 10-Q · filed 2017-11-03 | $333.19M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $48.33M 10-Q · filed 2017-08-04 | $58.55M 10-Q · filed 2016-08-05 | $112.09M 10-Q · filed 2017-08-04 | $130.25M 10-Q · filed 2016-08-05 | $236.49M derived: sum of 3 quarters · filed 2018-02-23 | $354.00M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $63.75M 10-Q · filed 2017-05-05 | $71.71M 10-Q · filed 2016-05-06 | $188.16M derived: sum of 2 quarters · filed 2018-02-23 | $305.67M derived: sum of 3 quarters · filed 2018-02-23 | $387.69M derived: sum of 4 quarters · filed 2018-02-23 | |||
| 2015-12-31 | $124.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $241.92M derived: sum of 2 quarters · filed 2018-02-23 | $323.94M derived: sum of 3 quarters · filed 2018-02-23 | $328.97M 10-K · filed 2018-02-23 | $356.92M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $117.51M 10-Q · filed 2016-11-09 | $123.95M 10-Q · filed 2015-11-06 | $199.53M derived: sum of 2 quarters · filed 2016-11-09 | $204.56M 10-Q · filed 2016-11-09 | $224.27M 10-Q · filed 2015-11-06 | $301.18M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $82.02M 10-Q · filed 2016-08-05 | $100.31M 10-Q · filed 2016-08-05 | $183.67M derived: sum of 3 quarters · filed 2017-02-28 | $268.12M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $18.29M 10-Q · filed 2016-05-06 | $101.64M derived: sum of 2 quarters · filed 2017-02-28 | $186.10M derived: sum of 3 quarters · filed 2017-02-28 | $264.37M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $83.35M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $167.81M derived: sum of 2 quarters · filed 2017-02-28 | $246.08M derived: sum of 3 quarters · filed 2017-02-28 | $281.85M 10-K · filed 2017-02-28 | $308.35M 10-K · filed 2015-03-09 | |||
| 2014-09-30 | $84.46M 10-Q · filed 2015-11-06 | $162.73M derived: sum of 2 quarters · filed 2015-11-06 | $198.49M 10-Q · filed 2015-11-06 | $284.16M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $78.27M 10-Q · filed 2015-08-06 | $114.04M 10-Q · filed 2015-08-06 | $199.71M derived: sum of 3 quarters · filed 2016-02-29 | $276.00M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $35.77M 10-Q · filed 2015-05-08 | $121.44M derived: sum of 2 quarters · filed 2016-02-29 | $197.73M derived: sum of 3 quarters · filed 2016-02-29 | $263.33M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $85.67M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $161.97M derived: sum of 2 quarters · filed 2016-02-29 | $227.56M derived: sum of 3 quarters · filed 2016-02-29 | $257.92M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $76.30M 10-Q · filed 2014-11-10 | $141.89M derived: sum of 2 quarters · filed 2014-11-10 | $172.25M 10-Q · filed 2014-11-10 | $246.60M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $65.60M 10-Q · filed 2014-08-08 | $95.95M 10-Q · filed 2014-08-08 | $170.31M derived: sum of 3 quarters · filed 2015-03-09 | $224.32M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | $30.36M 10-Q · filed 2014-05-12 | $104.71M derived: sum of 2 quarters · filed 2015-03-09 | $158.72M derived: sum of 3 quarters · filed 2015-03-09 | $211.88M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $74.35M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $128.36M derived: sum of 2 quarters · filed 2015-03-09 | $181.52M derived: sum of 3 quarters · filed 2015-03-09 | $215.88M 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $54.01M 10-Q · filed 2013-11-08 | $107.17M derived: sum of 2 quarters · filed 2013-11-08 | $141.53M 10-Q · filed 2013-11-08 | $223.20M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $53.16M 10-Q · filed 2013-08-06 | $87.52M 10-Q · filed 2013-08-06 | $169.19M derived: sum of 3 quarters · filed 2014-03-10 | $212.85M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | $34.36M 10-Q · filed 2013-05-03 | $116.03M derived: sum of 2 quarters · filed 2014-03-10 | $159.69M derived: sum of 3 quarters · filed 2014-03-10 | $231.17M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $81.67M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $125.33M derived: sum of 2 quarters · filed 2014-03-10 | $196.81M derived: sum of 3 quarters · filed 2014-03-10 | $202.41M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $43.66M 10-Q · filed 2012-11-01 | $115.14M derived: sum of 2 quarters · filed 2012-11-01 | $120.74M 10-Q · filed 2012-11-01 | $210.13M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-06-30 | $71.48M 10-Q · filed 2012-08-03 | $77.08M 10-Q · filed 2012-08-03 | $166.47M derived: sum of 3 quarters · filed 2013-03-08 | $233.73M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-03-31 | $5.60M 10-Q · filed 2012-05-04 | $94.99M derived: sum of 2 quarters · filed 2013-03-08 | $162.25M derived: sum of 3 quarters · filed 2013-03-08 | $218.13M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2010-12-31 | $89.39M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $156.66M derived: sum of 2 quarters · filed 2013-03-08 | $212.53M derived: sum of 3 quarters · filed 2013-03-08 | $251.38M 10-K · filed 2013-03-08 | ||||
| 2010-09-30 | $67.27M 10-Q · filed 2011-11-04 | $123.14M derived: sum of 2 quarters · filed 2011-11-04 | $161.99M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $55.87M 10-Q · filed 2011-08-05 | $94.72M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $217.17M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |